Telix Rallied Before the ASX Closed; Tuesday Trading in Focus
Telix Pharmaceuticals shares rose 3.26% to A$13.31 on Friday, outperforming a weaker ASX ahead of Monday’s King’s Birthday market closure. The gain followed updates on Telix’s prostate cancer trial data and a U.S. research deal with United Imaging. Telix’s stock is up 12.49% over four weeks but remains nearly 48% lower year-on-year. Investors await the next session after the holiday break.